Skin aging, laxity and regeneration

Source date: 2026-11-05. Recorded in this review: November 10, 2026. Evidence: Peer-reviewed randomized study; full paper appraised.

A seven-center Chinese trial randomized 446 participants to three monthly injections of hyamax noncrosslinked hyaluronic acid plus vitamin C/amino acids or no intervention. In the full-analysis set (218 versus 220), assessor-rated modified GAIS response was 84.9% versus 14.1%, four weeks after the third treatment; adjusted difference 70.69 percentage points (95% CI 63.23–76.52). This composite covers features such as dryness, pores, tone and fine lines.

Assessors were masked, but participants were not; no saline or needling comparator separated ingredient effects from the procedure and expectations. Follow-up beyond the controlled period cannot establish long-term comparative durability or tissue rejuvenation.

Any adverse events occurred in 101/218 versus 60/220; eight treated participants had possibly device-related events. No serious event was reported. A hyperpigmentation event lacked confirmed resolution after loss to follow-up, despite broader reassuring wording in the paper.

Next/U.S. status: No new U.S. authorization, matched registration or dated longer-term readout was verified.

Sources: Springer · article.

Source date: 2026-10-13. Recorded in this review: November 10, 2026. Evidence: October Phase 2 registration recovered; November status verified.

AbbVie's NCT07871513, first posted October 13 and updated November 5, records an actual October 8 start and recruiting status. The randomized, masked Phase 2 study plans 300 adults and multiple co-reconstituted trenibotulinumtoxinE/onabotulinumtoxinA arms, alongside onabotulinumtoxinA and placebo comparators. Numerical doses are not disclosed in the public record.

Primary measures include investigator-rated glabellar-line improvement at day seven and adverse events through day 150; onset and duration are additional endpoints. This corroborates the existence/start of the combination program mentioned in the October 30 management-call transcript, not its efficacy or a U.S. approval forecast.

Next: Primary and final completion are estimated for June 2028. The separate end-2026 resubmission/mid-2027 U.S. decision expectation for trenibotE monotherapy remains a management forecast documented in a third-party transcript; an actual FDA resubmission or decision was not verified. This entry recovers an October registration rather than announcing a new November study.

Sources: ClinicalTrials.gov · NCT07871513; stockanalysis.com · source page.

Source date: 2026-11-06. Recorded in this review: November 10, 2026. Evidence: New exploratory registry protocol; no results.

Project Skin MD registered NCT07923448 to test whether subsequent trenibotulinumtoxinE shortens onabotulinumtoxinA's effect on crow's feet. The narrative describes a randomized split-face comparison against placebo, with only four planned participants, measuring time until wrinkles return to baseline through day 120. It is not yet recruiting and supplies no evidence that trenibotE works as an antidote or reverses unwanted toxin effects.

The registry has unresolved drafting inconsistencies: placeholder text remains for sample size, follow-up and rating scale; its structured design says parallel while the narrative is within-person. Estimated start and primary completion both fall in December 2026, which does not fit a complete 120-day follow-up; final completion is estimated March 2027.

Next: Verify actual recruitment/start and a coherent, finalized protocol. Do not promise a December result or infer a new approved reversal treatment from this registration.

Sources: ClinicalTrials.gov · NCT07923448.

Coverage and remaining gaps: Focused/incomplete review; do not advance the full successful-check timestamp. Named CT.gov records and bounded discovery/paper searches were retrieved, but this is not complete worldwide registry, regulator, conference, device/procedure, safety or audio coverage. Retrieval continued after the scheduled 9 a.m. heartbeat; source dates are preserved. Twenty named records and 26 November 3–10 discovery records retrieved; the broader September 5 onward registry query timed out. The 87-record paper search was selectively appraised. New small Rejuran estimated starts remain unconfirmed. KB304 Phase 2 forecasts and trenibotE U.S. resubmission are not achievements. ASDS exosome/digital-toxin claims lacked complete numerical posters; no additional efficacy event selected.

Informal-source coverage: Revisited the October 30 management transcript: combination-study existence/start is now registry-corroborated, while end-2026 resubmission/mid-2027 U.S. decision remains a forecast. Indexed Reddit and skin-aging podcast/talk searches found no selected new specific rumor; full audio and ASDS Q&A were not appraised.

Full coverage record.

Source date: 2026-11-03. Recorded in this review: November 3, 2026.

First posted November 3, PharmaResearch's NCT07912879 and NCT07912814 each plan 30 adults aged 25–65 at Southeast Asian sites, receiving four Rejuran S/DOT-PN sessions four weeks apart, with 24-week follow-up. Both are registered as observational, prospective case-only studies, without a comparison group.

The neck study measures 3D wrinkle-depth change at week 16; the periorbital study measures tear-trough depth and brow height separately. Patient appearance assessments and adverse events are also planned. Both specify study-specific cannula techniques; the neck record explicitly says its deeper-plane technique differs from the product instructions.

There are no visible-improvement, volume-retention, regeneration or safety results. Wrinkle depth, hollowing and brow position are distinct endpoints. Neck start November 15 and eye-study start December 7 are estimates; both remain not yet recruiting. No U.S. approval or availability is established by these registrations.

U.S. status: No new U.S. authorization follows from this study or registration.

Next milestones: Rejuran S neck study estimated start: 2026-11-15 (Registry estimate; not yet recruiting); Rejuran S periorbital study estimated start: 2026-12-07 (Registry estimate; not yet recruiting).

Sources: ClinicalTrials.gov · NCT07912879; ClinicalTrials.gov · NCT07912814.

Related findings, recorded once: A recombinant-enzyme umbrella study adds fat and cellulite subtracks (ClinicalTrials.gov · NCT07908953).

Coverage and remaining gaps: focused_incomplete; do not advance full successful-check timestamp. Complete retrieval for these bounded queries is not complete worldwide clinical appraisal. Full international registry, conference, device/procedure, detailed safety and audio coverage remains incomplete.; Full independent device/procedure harms and skin-type-specific comparative review incomplete. KB304 phase 2 actual start remains unverified beyond saved forecast; current collection refresh does not establish a new regulatory decision on trenibotE.; New PN records are nonrandomized observational case-only cohorts with no control, no posted results and study-specific cannula techniques differing from product instructions.

Informal-source coverage: Targeted Reddit/podcast searches for rejuvenation, polynucleotides, KB304 and devices sampled. Found older personal/procedural discussions without a distinct new, attributable formal-program rumor; full audio/comment census incomplete.

Full coverage record.

Source date: 2026-10-28. Recorded in this review: October 30, 2026.

A new October 28 report describes three monthly full-face IPL treatments in a Chinese single-center cohort from 2022–2023. Of 230 enrolled adults, 217 completed; 208 were women and all had Fitzpatrick III–IV skin. There was no untreated or active comparator.

The body reports reactions in 100/217 (46.1%). Table 3 lists hyperpigmentation in 12/217 (5.5%), hypopigmentation in 8/217 (3.7%) and acne-like eruptions/milia in 20/217 (9.2%); categories overlap. Pigment reactions reportedly lasted weeks to months. Short follow-up and selective self-reporting cannot establish long-term incidence or compare devices.

Efficacy is internally inconsistent: the abstract gives 65.9%/33.2%, whereas the results give 53.5%/12.4% for its improvement categories. The methods describe ethics approval and consent, while the declarations say neither. These discrepancies need clarification; do not use the abstract as a reliable efficacy estimate or infer a new regulatory warning. This adds limited procedural-harms context rather than proof of durable skin rejuvenation.

U.S. status: No new U.S. clearance, approval or regulator warning established by this paper.

Next milestones: Clarification of IPL publication discrepancies: date unknown (No announced date).

Sources: primary source; Springer · article.

Coverage and remaining gaps: focused_incomplete; do not advance full successful-check timestamp. Focused incomplete appraisal only; complete retrieval for these bounded queries is not complete worldwide clinical review. Full successful-check timestamps remain unchanged. Independent national registries, every conference appendix, all device/procedure safety and all podcast audio/comments remain incomplete.; Full source correction/author clarification of IPL efficacy and ethics inconsistencies is outstanding; rare harms and longer durability unestablished.; No verified new trenibotE US decision or exhaustive device-clearance census.

Informal-source coverage: Sampled original episode notes and indexed aesthetic interviews, Reddit and podcast leads. October26 DermSurgery Digest is commentary on published studies, not a new controlled readout; full audio and all transcripts were not appraised. No selected new rumor/status change.

Full coverage record.

Source date: 2026-10-24. Recorded in this review: October 27, 2026.

An October 24 full paper reports M21-500 (NCT05248867), conducted in 2022–2023; registry results were already posted in 2024. This is fuller publication, not a newly conducted trial.

Among 638 randomized adults, 700 units of trenibotulinumtoxinE produced the day-7 joint participant/investigator glabellar-line response in 60.0% (95% CI 55.5–64.4) versus 0.6% (0–1.9) with placebo. Improvement was detected at the first eight-hour assessment; most returned to moderate/severe lines by day 21. Serotype E units are not interchangeable with Botox units.

During double-blind follow-up, any treatment-emergent event occurred in 118/482 versus 44/156; serious events in 3/482 versus 1/156, none judged treatment-related. Four active recipients discontinued for adverse events. One possible toxin-spread event occurred during double-blind follow-up; additional events occurred after retreatment. Authors did not judge the events consistent with distant spread. This cannot establish zero risk or superiority to a longer-acting toxin: there was no active comparator, and participants were predominantly White and female.

U.S. status remains the April 23 manufacturing-related complete response letter; this paper is not FDA approval. The endpoint is temporary dynamic wrinkle reduction, not restoration of facial volume or proof of generalized skin rejuvenation.

U.S. status: April 23, 2026 sponsor-reported manufacturing CRL remains the verified U.S. regulatory position; no new FDA decision date verified.

Next milestones: TrenibotE U.S. resubmission or FDA decision: date unknown (No verified date; do not infer from this publication).

Sources: DOI · 10.1093/asj/sjag198; PubMed · PMID 42926352; ClinicalTrials.gov · NCT05248867; AbbVie · source page.

Coverage and remaining gaps: focused_incomplete; do not advance full successful-check timestamp. Worldwide completion is not established: CTIS, ChiCTR/jRCT and other national registries, every indexed article, every conference poster and unindexed social/audio sources were not exhaustively appraised. Keep the full successful-check timestamp unchanged.; No complete census of new aesthetic-device clearances, worldwide launches or rare long-term adverse events.; Oral hyaluronan and pomegranate supplement papers surfaced but were not fully appraised for prespecified primary clinical outcomes; do not convert exploratory elasticity/biomarker changes into durable visible rejuvenation.; No new U.S. trenibotE resubmission or decision date was verified.

Informal-source coverage: scope: Indexed Reddit, aesthetic-clinic claims and named product/podcast/interview searches sampled; original sponsor/regulatory statements preferred.; status: No selected new rumor or material status change. Promotional procedure claims without a new formal human result were not promoted.; limitations: No exhaustive clinic-interview transcripts or podcast audio reviewed.

Full coverage record.

Source dates: NOA HYDRATION first posted October 19; MD60002 October 20, 2026. Evidence: new human-trial registrations, no outcomes.

NOA HYDRATION / NCT07880756: An AbbVie-sponsored, assessor-masked randomized study plans 150 Chinese adults, allocated 2:1 to injectable treatment or two months of no-treatment control. The registry lists recruiting and an actual September 16, 2026 start. Co-primary measures include bilateral cheek-smoothness response, investigator global appearance and adverse events; visible benefit is assessed at month two, with treated participants followed up to twelve months. The public intervention description does not disclose a full composition: do not assume a specific hyaluronic-acid formulation. February 2028 primary/final completion remains an estimate.

MD60002 / NCT07881926: Promoitalia plans a single-center, uncontrolled, open-label study of 43 adults in Italy using a 3% fish-derived polynucleotide gel. Wrinkles, satisfaction and safety are assessed approximately thirty days after final treatment. It is not yet recruiting. November 20, 2026 is listed as both estimated start and primary completion despite the treatment/follow-up schedule; resolve that inconsistency before forecasting results. Final completion is estimated April 1, 2027.

Limits and U.S. status: Registration supplies no comparative efficacy, durability or safety result and no new FDA authorization. NOA's short untreated comparison cannot establish twelve-month comparative benefit; MD60002 lacks a control. Hydration/appearance improvement is distinct from proven tissue regeneration, correction of substantial laxity or restoration of lost facial volume.

Sources: ClinicalTrials.gov · NCT07880756; ClinicalTrials.gov · NCT07881926.

Coverage and remaining gaps: Read the current authoritative topic and watch scope. September 5–October 20 window retains overlap from the September 12 full successful check; changes since October 16 prioritized and prior canonical findings deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (90 records) and all 11 saved named records. Incidental matches excluded. Full successful-check timestamp must remain unchanged.; Exact-phrase Europe PMC MED discovery retrieved 60 of 60 returned records, with selective title/abstract appraisal. An initial unquoted search produced incidental broad matches and was replaced with these complete bounded exact-phrase queries. Retrieval is not exhaustive worldwide full-text appraisal.; International registry census, every device/procedure, complete conference appendices, all full safety tables and original podcast/audio coverage remain incomplete. No additional selected finding is not a full-topic no-news conclusion.; October 23 delta: bounded dated discovery returned older studies, reviews and cosmetic/mechanistic leads rather than a selected new October21–23 human outcome. Full journals, original conference abstracts, regulatory and device census not repeated.

Informal-source coverage: Targeted indexed Reddit, named-program and talk/podcast queries were reviewed. Routine self-experimentation, clinic advertising and repeated existing source claims were not treated as formal outcomes. Unindexed comments and original audio remain coverage gaps. October 23 delta remains a bounded indexed-source check; no newly selected material rumor status change. Original audio and unindexed comments remain incomplete.

Full coverage record.

An October 9 peer-reviewed publication reports SB-NASHA (Restylane Skinboosters Vital Lidocaine) microinjections for moderate-to-severe décolletage wrinkles. The main study randomized 192 women, 144 to three treatment sessions and 48 to no treatment; 19 additional women with Fitzpatrick V–VI skin entered safety follow-up without randomization.

At week 12, blinded-evaluator response (at least one wrinkle-severity grade) was 73.6% versus 18.8%. The posted registry reports a 54.9-percentage-point difference (95% CI 41.7–68.0). At week 32, observed-case response was 80.8% versus 40.9%; later percentages have different evaluable denominators.

Safety: Treatment-related adverse events affected 32/163 treated participants (19.6%); none were serious. Diary-reported injection reactions were more common: 92.4% after the first session, usually resolving within one to two weeks. Some adverse events lasted longer, so brief downtime is not universal.

Limits and U.S. status: This Galderma-funded study had no sham injections; randomized efficacy largely concerns skin types I–IV. Safety follow-up extended to week 56 but cannot exclude rare harms. No current U.S. approval for this precise formulation/indication was verified. Registry results first posted July 15; October 9 is publication, not first disclosure.

Sources: DOI · 10.1097/DSS.0000000000005381; PubMed · PMID 42847981.

Remaining gaps: Read current canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and this entire topic page. Search window September 5–October 16 preserves overlap from September 12 full successful check; October 14–16 changes prioritized and all saved October 13 material deduplicated. Retrieved every page of bounded ClinicalTrials.gov discovery (78 returned records) and all 10 named records. Retrieved records were selectively appraised; incidental matches excluded. Do not advance full successful-check timestamp.; Newly appraised October 9 SB-NASHA randomized publication is an evidence upgrade and a new-to-watch clinical comparison; registry results were already posted July 15. Preserve publication versus first disclosure dates.; Sofwave October 5 release repeats the June 1 paper already saved October 9; no duplicate news. Newly posted October 14–16 studies include small single-arm MD60000 and completed thread/cream pilots without results; not promoted as demonstrated benefit. MD60000 registry has same-day estimated start and primary completion and requires clarification before calendar use.; No current U.S. approval for the precise SB-NASHA décolletage formulation/indication was verified. Manufacturer brands and paper-era availability do not settle current FDA status. Full FDA/IFU census, complete non-U.S. procedures, every publication and rare-event long-term safety remain incomplete.

Informal-source coverage: Reddit skin-aging/rejuvenation queries and primary/podcast discovery reviewed; Sofwave promotional episode and sponsor announcement repeat the already saved study. No new specific high-value claim selected. Full audio, transcripts and unindexed conversations were not exhaustively reviewed.

Full coverage record.

First registry posting October 13, 2026; reported actual start September 3. NCT07870694, Huons Biopharma, lists a recruiting randomized, participant/investigator-masked Phase 3 comparison in 390 planned adults aged 19–65 with moderate/severe glabellar lines. HU-045 and Xeomin are given at five 4-unit glabellar sites. The primary measure at week 4 requires investigator-rated lines to become none/mild with at least two grades of improvement; later assessments and satisfaction extend through week 16.

Limits/safety: No efficacy or adverse-event results. Temporary neuromuscular wrinkle smoothing does not establish skin regeneration, laxity treatment or facial-volume restoration. The structured phase and official title say Phase 3, while the brief summary still says PhaseII; retain the metadata discrepancy pending clarification. Registry description associates HU-045 with botulinum toxinA/incobotulinumtoxinA, but does not establish interchangeability with Xeomin or superiority.

U.S.: This Korean study establishes no U.S. approval or availability for HU-045. Next: primary completion May 2027 and final completion August 2027 are registry estimates, not readout promises.

Original registry.

Remaining gaps: Read canonical README, HOW_THIS_WORKS, WATCHLIST, catalog, state, LATEST, MILESTONES, LANDSCAPE and assigned current topic. September 5–October 13 window preserves seven-day overlap from September 12 full successful check. Retrieved every page of bounded public registry discovery (70 returned records; incidental matches excluded), and all named records. Full successful-check date must remain unchanged.; Europe PMC retrieval now succeeded, closing prior HTTP503 access failure. Initial broad query downloaded up to 100 per topic with many incidental/nonhuman matches; title/abstract MED retry retrieved hair 97/97, skin 27/27, scars 25/25, dental 100/147. Retrieved records are not an exhaustive worldwide full-paper/safety appraisal.; New HU-045 glabellar-line Phase 3 registry appraised. KB304 remains active/not recruiting with stale 2025 estimate; ellacor nine-person cohort remains completed/no results. Existing post-weight-loss and secretome/energy-device claims deduplicated. RLS-1496 hair plan belongs to hair_loss; October 12 AK investigator interview is newly posted secondary context, not verified wrinkle rejuvenation. Original EADV228 abstract, full photoaging numerical tables, device clearance/rare-harm census remain gaps.

Informal-source coverage: September 22 Hot Water episode with Christie Prendergast found in original Apple listing and secondary Podcast Rex description; secondary summary attributes a clinic secretome trial plan but full transcript fetch failed, original audio/time passage unverified and possible overlap with saved Acorn program unresolved. Kept as follow-up lead, not newly verified trial or quoted statement. October 12 RLS posts frame senescence changes as age reversal; this interpretation is not proven clinical rejuvenation. Full originals remain gaps.

Full coverage record.

Historical publication: June 1, 2026; October 5 sponsor promotion is not a fresh efficacy readout. Baseline addition.

A prospective uncontrolled Hong Kong series treated 42 Asian adults aged 35–67 once with high-intensity, nonfocused parallel ultrasound across face, neck and submental regions. Physician-rated submental/neck improvement occurred in 83.3% at three months. The objective jawline/submental volume change was −1.04 ± 3.49 mL, p=.06; this did not establish a statistically reliable effect or selective fat reduction. The abstract's wrinkle/elastosis measure differs from the sponsor's headline laxity percentages; do not combine them into one durability response rate.

Safety and limits: Initial erythema affected 50% and edema 7.2%, resolving at follow-up; no other events were documented. Small size, no comparator, open assessments and missing full appraisal limit efficacy, durability and rare-harm conclusions. This is not correction of substantial post-weight-loss excess skin. Exact FDA-cleared indication/version should be read separately; no new U.S. clearance occurred in this report. Next: independent controlled comparisons and complete long-term data, undated.

Original publication; October 5 sponsor release.

Remaining gaps: Read the current assigned topic and canonical scope/state. Named original registry records refreshed; all pages of broad ClinicalTrials.gov discovery for September 5–October 9 were retrieved (41 records, with incidental matches excluded). This honors the seven-day overlap from the saved September 12 full successful check.; Europe PMC original-literature discovery again returned HTTP 503. Targeted primary publisher, sponsor and conference searches were performed, but the worldwide paper/regulator/procedure and original-audio census remains incomplete. Preserve last_successful_check_utc.; KB304 remains active/not recruiting with stale 2025 completion estimate; no Phase 2 actual initiation verified. Ellacor nine-person completed/no-results cohort and AnteAGE pilot registrations already captured October 6. FDA RF-microneedling communication remains older ongoing evaluation, not relabeled a new alert.; Sofwave June paper full text redirected to abstract; October 5 sponsor promotion deduplicated by actual paper date. September 22 multimodal RF RCT full appraisal and world device clearance/rare-complication census remain incomplete. PRX S acne-prone skin NCT07866131 is an observational cosmetic protocol, no outcome.

Informal-source coverage: October 6 Vitality Unfiltered David Bauder/Alicia Sanderson episode https://www.buzzsprout.com/2542776/episodes/19774930-sofwave-non-surgical-skin-tightening-collagen-facial-rejuvenation-with-alicia-sanderson-md?t=0 was found as original show description. It concerns existing procedures, not a verified new trial milestone; full audio/transcript not reviewed. Earlier Lufkin/Durairaj rapalog/GLP-1-face lead remains unappraised. No new rumor selected.

Full coverage record.

Source date: October 5, 2026 registry posting. Reported actual completion: August 21, 2026.

NCT07224880 now lists a completed prospective U.S. ellacor micro-coring cohort with nine actually enrolled adults aged 30–65. Its named GLP-1 cohort had lost at least 10% of baseline weight. Planned assessments cover safety and appearance through approximately 90 days across Fitzpatrick skin types I–VI. No results are posted. This small, uncontrolled cohort cannot establish durable correction of post-weight-loss laxity, broad skin-type safety or superiority to another procedure. Completion is a development milestone, not evidence of successful tightening or a new U.S. clearance. Next: results publication and longer controlled follow-up, with no verified release date.

Original registry.

Source/event date: September 30, 2026 first registry posting. Historical study: August–November 2025.

NCT07849205 discloses a completed, uncontrolled U.S. pilot in 12 adults aged 35–65 receiving mechanical microneedling with AnteAGE Exosomes, PEARL Multiplier and a multicomponent home-care regimen. Twelve-week outcomes include skin-retraction time, VISIA coarse-wrinkle area and water loss. No results are posted. This is a separate study from the already recorded 30-person biosome/radiofrequency comparison, not an independent replication of that regimen. Retrospective registration, no control and multiple concurrent products prevent attribution to exosomes. Planned elasticity/barrier measurements do not prove tissue regeneration or durable laxity correction; safety results and a new U.S. authorization are not established. Next: results and component-controlled replication, undated.

Original registry.

Source/event date: 2026-09-30. Evidence: New registry disclosure of a historical pilot; no results.

A newly posted registry record describes a completed, randomized, masked 30-person pilot of radiofrequency microneedling with AnteAGE Biosome Solution and accompanying skin care versus the same procedure with hyaluronic-acid glide and control skin care. Outcomes include early reactions, wrinkles/discoloration and adverse events through 60 days. Actual study dates were December 2024–June 2025; first posting was September 30, 2026. This is retrospective disclosure, not a newly recruiting trial or positive efficacy readout. The intervention uses lipid vesicles; it should not be described as a proven stem-cell or tissue-regeneration treatment. No results are posted and no U.S. approval for this regimen was verified. Registry.

Next milestone: Results publication: date unknown.

ClinicalTrials.gov · NCT07849556.

Source/event date: 2026-09-28. Evidence: Peer-reviewed primary abstract; full-text appraisal incomplete.

In a prospective study of 25 women, both facial sides received radiofrequency microneedling; the right side received 2 mL Rejuran polynucleotide and the left saline. At six weeks, pore-score improvement was 4.79 versus 0.95 and wrinkle-score improvement 5.04 versus 3.67 (both p<0.001). Dermal-thickness and elasticity differences were not significant. This fixed-side, small study does not establish durable tightening or regeneration, and score changes are not directly interpretable as percentage cosmetic improvement. Full adverse-event counts and longer follow-up were not available in the abstract; full text could not be appraised. This is not a U.S. approval update. Primary publication abstract.

Next milestone: Longer controlled follow-up: no announced date found.

Primary publication abstract; DOI · 10.1097/GOX.0000000000008109.

Source date: 2026-09-22. Evidence: trial-registry registration.

A UK study will compare OCT imaging and skin-fluid biomarkers with biopsies while testing short exposures to marketed cosmetic products. ISRCTN10674073 targets 24 younger adults and adults aged 45+ with photodamage. Older participants receive four randomized product patches and control areas over 12 days; the primary focus is measurement validation. The September 22 record lists recruiting.

Limitations: No efficacy results. Biomarkers and exaggerated-use patches do not establish durable visible rejuvenation. The record labels registration prospective despite listing first enrollment September 14, before September 22 registration. Its plain-language September–December 2026 schedule also differs from structured completion May 3, 2027.

Safety: Planned biopsy and product-tolerability monitoring; no safety results.

U.S. status: No new U.S. treatment approval; this is a UK methods/cosmetic study.

Next milestone: Resolve registry chronology and completion discrepancies; public results timing unknown.

Primary ISRCTN record.

Source date: 2026-09-23. Event date: 2026-09-23. Evidence: investigator/practice announcement; preliminary human study and conference schedule.

Bauman Medical announced an October presentation comparing a hair-follicle-derived secretome with PRP; its biochemical measurements do not establish better hair regrowth. The announcement describes a post-ablative-laser recovery pilot in 11 people, reporting 32–58% reductions in recovery symptoms versus comparators. It also compares proteins and exosome particles in preparations from the same donors. The cited NCT06477172 is a separate prospective observational study, recruiting with 500 planned participants and February 2027 estimated completion; its primary outcomes are short-term post-procedure symptoms and downtime.

Limitations: Sponsor/practice account without the complete abstract, allocation methods, confidence intervals or full clinical tables. Product-composition differences are not hair-density or durable rejuvenation outcomes. Investigator disclosed research and ownership relationships.

Safety: The release provides no detailed adverse-event table; small early recovery observations cannot establish rare or long-term safety.

U.S. status: The announcement explicitly says aHFS is investigational and not FDA cleared or approved.

Next milestone: ISHRS congress October 15–17, 2026; the release does not specify an exact presentation day. Await the actual abstract and controlled clinical outcomes.

Bauman Medical announcement; Acorn observational study.

Related findings:

• A placebo-controlled hair-graying trial enters the registry.

Source date: 2026-09-15. Event date: 2026-09-15. Evidence: peer-reviewed randomized human pilot; abstract appraised.

A longer-pulse IPL regimen was more comfortable, but did not show a statistically reliable advantage on the measured objective skin outcomes. Twenty-seven Chinese participants with mild-to-moderate photoaging received three sessions: 80-ms/higher-fluence IPL (13) versus 15-ms/lower-fluence IPL (14). At three-month follow-up the pore-count difference was −264.5 (95% CI −466.9 to −62.1), nominal p=.0127, but Holm-adjusted p=.0635. The other four objective endpoints were also nonsignificant after correction. Pain and satisfaction favored 80 ms.

Limitations: Small exploratory trial; complete regimens differ in both pulse duration and fluence, so effects cannot be attributed to pulse width alone. No sham control. Full paper and registry matching remain gaps.

Safety: Mild self-limited adverse events; no serious events, blistering, edema, pigment alteration or scarring reported in this small sample.

U.S. status: No new U.S. clearance established.

Next milestone: Larger controlled comparisons and durability results undated.

Original abstract; Original DOI.

Related findings:

• Topical facial-volume pilot provides early imaging evidence with substantial limitations.

Source date: 2026-09-17. Evidence: sponsor conference report; preliminary human studies.

Allergan reports early skin-quality improvements in people taking weight-loss medicines, from two very small single-center studies. One 12-week skincare study had nine completers; a six-week DiamondGlow plus skincare study had 11 people with at least one post-treatment assessment. Selected investigator-rated dryness, texture, crepiness and other measures improved.

Limitations: The release supplies no randomized comparator, numerical effect sizes, uncertainty intervals or enrollment denominators. Its perceived younger-appearance claims are participant impressions, not biological-age reversal or evidence of substantial loose-skin correction.

Safety: Adverse-event counts were not supplied; do not describe the regimens as proven safe.

U.S. status: No new FDA indication or approval announced.

Next milestone: Posters at Science of Skin Summit September 17–20; full controlled replication and durability results undated.

AbbVie original release.

Jeune Aesthetics/Krystal's investigational intradermal gene therapy is being developed for upper-chest wrinkles. PEARL-2, NCT06724900, randomized 19 women to KB304 or placebo; 18 were assessed after one participant withdrew before completing treatment. In the sponsor's July 24, 2025 report, investigator-rated improvement at three months occurred in 11/11 treated participants versus 2/7 controls; participant-rated improvement occurred in 8/11 versus 1/7. Reported adverse events were mild or moderate, with no severe or drug-related serious events. This is a small Phase 1 signal with short follow-up, not established long-term rejuvenation or evidence for other body sites. Sponsor results

Next: the August 3, 2026 company update targets Phase 2 initiation in 2027, superseding the older first-half-2026 plan. This is a sponsor forecast for trial start, not a results or approval date. No U.S. marketing approval or dependable readout date was verified. Current filing, page 6

Topical tretinoin provides a useful efficacy benchmark for newer products. A two-year randomized vehicle-controlled study of 204 participants found greater improvement in facial photodamage with tretinoin 0.05%, including wrinkles and uneven pigmentation. Increased procollagen staining was a separate biological measurement. The trial does not establish meaningful removal of loose skin after major weight loss. Monitor genuinely improved tolerability, adherence and comparative performance of newer formulations, rather than treating another collagen claim as a breakthrough. No specific upcoming pivotal readout was verified in this baseline. Primary trial

A February 27, 2026 randomized Chinese study compared YOUMAGIC monopolar radiofrequency with Thermage CPT in 230 enrolled participants, with 212 in the final analysis and six-month follow-up. The reported day-90 GAIS threshold was reached by 100% versus 98.1%; the investigators concluded noninferiority. This active-comparator design does not show superiority over sham, and percentage responders are not the percentage of loose skin removed. The registry identifier is ChiCTR2400087993, retrospectively registered. The abstract reported no serious adverse events; U.S. clearance of the specific YOUMAGIC device was not established in this check. Primary study

Keep monopolar RF, RF microneedling, focused ultrasound and lasers distinct. FDA's October 15, 2025 RF-microneedling communication describes reported burns, scarring, unwanted fat loss, disfigurement and nerve injury; it says evaluation is ongoing. The communication does not supply a complication incidence or prove all RF technologies share the same risk. Future trials should measure visible benefit alongside unintended volume loss, pigmentation changes and recovery. FDA communication